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pating ICUs adopted the use of a standard care 
plan including temperature management soon 
after the seminal articles,1,2 making the excellent 
survival rates depicted in this graph representa-
tive of the “temperature-management era.” Sec-
ond, the relevant comparison group for baseline 
survival from the Hypothermia after Cardiac Ar-
rest Study Group trial1 is the control group, which 
received no regimented care with respect to tem-
perature management. Although control patients 
were highly selected from a group with a high 
likelihood of survival, hospital mortality was 50% 
(69 of 138 patients), substantially higher than the 
hospital mortality of 44% (411 of 939 patients) in 
the TTM trial involving less selected patients. 
Third, if the ANZICS APD includes patients ad-
mitted to the ICU, it may not capture deaths that 
occur in the emergency department or during 
pre-ICU procedures. Despite this limitation, we 
do appreciate a modest decline in hospital deaths 
over the decade from more than 60% to its cur-
rent level.
Jon C. Rittenberger, M.D. 
Clifton W. Callaway, M.D., Ph.D.
University of Pittsburgh 
Pittsburgh, PA
Since publication of their editorial, the authors report no 
further potential conflict of interest.
1. The Hypothermia after Cardiac Arrest Study Group. Mild 
therapeutic hypothermia to improve the neurologic outcome after 
cardiac arrest. N Engl J Med 2002;346:549-56. [Erratum, N Engl J 
Med 2002;346:1756.]
2. Bernard SA, Gray TW, Buist MD, et al. Treatment of coma-
tose survivors of out-of-hospital cardiac arrest with induced hypo-
thermia. N Engl J Med 2002;346:557-63.
DOI: 10.1056/NEJMc1401250
BMI and Mortality among Adults with Incident Type 2 Diabetes
To the Editor: Tobias et al. (Jan. 16 issue)1 
found no evidence of lower mortality among 
obese patients with incident type 2 diabetes, as 
compared with their normal-weight counterparts. 
An “obesity paradox” (i.e., an association between 
obesity and reduced mortality) had been reported, 
in particular in patient populations with a short 
survival time, whereas obesity by its nature is a 
risk factor for increased long-term mortality. Our 
earlier results show that short follow-up and the 
advanced age of populations with chronic dis-
eases are major limitations of such studies: over 
short periods, a high body-mass index (BMI) was 
not associated with increased mortality among 
patients with end-stage renal disease, but it was 
also not associated with increased mortality in 
the general population of equal age.2 Moreover, 
different underlying causes of the disease and 
coexisting illnesses impede a valid comparison 
between patients with a high BMI and those with 
a low BMI. Because of these limitations, it is not 
possible to translate such observations into causal 
interpretations — for example, to advise a high 
body weight in these patients. The findings by 
Tobias et al. are a timely reminder of the many 
biases that need to be taken into account before 
a causal interpretation of population data is pos-
sible.
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To the Editor: Although Carnethon et al.1 found 
a better prognosis in obese patients with type 2 
diabetes as compared with patients of “normal” 
weight, Tobias and colleagues did not find an 
obesity paradox. They explained that prior analy-
ses were limited by short follow-up, a small num-
ber of deaths, and a lack of data on smoking or 
undiagnosed diseases.
We are concerned, however, that neither study 
mentioned above accounted for fitness, espe-
cially because obese but fit persons with type 2 
diabetes have a considerably better prognosis 
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than lean and unfit persons.2 We found that fit-
ness alters the relationship between adiposity 
and prognosis in pre–type 2 diabetes, coronary 
heart disease, and heart failure.3,4 Despite the 
fact that physical activity was approximately 25% 
lower in overweight or mildly obese participants 
(BMI [the weight in kilograms divided by the 
square of the height in meters], 27.5 to 34.9) and 
approximately 50% lower in moderately obese 
participants (BMI, ≥35) than in normal-weight 
participants (BMI, 18.5 to 24.9) in the study by 
Tobias et al., we were surprised that they did not 
correct for physical activity in their multivariate 
analyses. We wonder whether one can adequately 
adjust for such huge differences, similar to their 
expressed concerns about smoking. We suspect 
that an obesity paradox would be present in 
those with type 2 diabetes and low physical 
activity or fitness.
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To the Editor: Tobias and colleagues reported a 
linear relationship between BMI and mortality in 
type 2 diabetes, in contrast to the J-shaped rela-
tionship observed in other studies, including our 
own large, general population–based study.1 We 
performed analyses that excluded smokers, ad-
justing for cardiovascular risk factors and exclud-
ing deaths within 5 years (to account for coexist-
ing conditions), with no attenuation of results, 
and we had the advantage of physician-reported 
weight and diabetes diagnosis.
The conflicting results may partially reflect 
the timing of the studies; our data were mainly 
from 2000 and after, whereas Tobias et al. have 
analyzed data from the 1970s. Not only have 
there been substantial increases in body mass 
since then, there have also been improvements 
in the management of diabetes and the life ex-
pectancy of patients with the disease, which may 
have been disproportionate across the range of 
BMI categories. We would suggest that to resolve 
differences, further studies with the use of con-
temporary data in the general population are 
needed. Lifestyle-intervention studies would be 
even better but, given decreasing mortality in dia-
betes, difficult to power.
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To the Editor: The analysis of BMI and mortal-
ity by Tobias et al. contradicts recent studies on 
the obesity paradox proposing that weighing 
more than “normal” may provide a mortality ad-
vantage in type 2 diabetes. All these studies share 
weaknesses. The notion of an obesity paradox 
arises from the biologically implausible concept 
that humans throughout their life cycle have a 
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constant, optimal weight range that is not al-
tered by age, sex, ethnic group, or state of health. 
Consistent reports indicate that with aging1 and 
a growing list of chronic diseases characterized 
by compromised nutrition, sarcopenia, weakness, 
impaired physical function, and frailty,2,3 the na-
dir of the mortality:weight curve is in the “over-
weight” or “class I obese” range. Additional lean 
or fat reserves, not adequately measured by weight 
or BMI, may be adaptive, providing resilience, 
and therefore the elderly overweight and class I 
obese (by younger normative standards) patients 
benefit more from lifestyle programs focused on 
quality nutrition, physical activity, fitness, and 
maintenance of function4 than from achieve-
ment of “normal” weight, which may mask sar-
copenia.
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The authors reply: We agree with de Mutsert 
et al. that studies with short follow-up or of older 
patient populations may be especially prone to 
reverse-causation bias, owing in part to the in-
fluence of underlying illnesses.
Lavie et al. raise the potential of confounding 
by fitness in our analysis; however, adjustment for 
physical activity with the use of our validated 
measure did not appreciably alter the results. 
Physical activity was actually included in our 
multivariable models, as described in the Statis-
tical Analysis section. We inadvertently omitted 
physical activity from the list of covariates in 
multivariable models in the tables and figures. 
In further analyses (Table 1), we found that the 
Table 1. Hazard Ratios for All-Cause Mortality among Participants with Incident Type 2 Diabetes, According to BMI Shortly before Diagnosis 
of Type 2 Diabetes, Smoking Status, and Physical Activity Level.*
Variable
No. of 
Deaths/ 
Person-Yr Hazard Ratio According to BMI Category (95% CI)
P Value 
for Linear 
Trend
18.5–22.4 22.5–24.9 25.0–27.4 27.5–29.9 30.0–34.9 ≥35.0
Total participants
Low physical  
activity level
1612/87,394 1.13 
(0.83–1.54)
1.00 1.12 
(0.92–1.38)
1.11 
(0.77–1.60)
1.07 
(0.87–1.30)
1.26 
(1.02–1.55)
<0.001
High physical  
activity level
1158/71,478 1.44 
(1.05–1.96)
1.00 1.13 
(0.92–1.39)
1.17 
(0.93–1.46)
1.55 
(1.27–1.91)
1.34 
(1.04–1.73)
0.009
Those who never smoked
Low physical  
activity level
598/13,272 1.55 
(0.90–2.66)
1.00 1.36 
(0.93–1.99)
1.46 
(1.01–2.13)
1.28 
(0.90–1.84)
1.60 
(1.11–2.32)
0.03
High physical  
activity level
441/31,330 1.02 
(0.30–3.51)
1.00 1.17 
(0.83–1.65)
1.18 
(0.48–2.92)
1.84 
(0.87–3.88)
1.64 
(0.90–3.00)
<0.001
* Shown are the results for the combined Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts. The re-
sults for the two cohorts were combined with the use of a fixed-effect meta-analysis. In the NHS cohort, P = 0.19 for interaction in total 
participants and P = 0.08 for interaction in those who never smoked. In the HPFS cohort, P = 0.30 for interaction in total participants and 
P = 0.37 for interaction in those who never smoked. Data were adjusted for age, race, marital status, menopausal status (for the NHS co-
hort only), presence or absence of a family history of diabetes, smoking status, alcohol intake, and Alternate Healthy Eating Index score. 
The low physical activity level was defined as less than nine metabolic-equivalent tasks per week, and the high physical activity level as 
nine or more metabolic-equivalent tasks per week. CI denotes confidence interval.
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association between BMI and mortality was simi-
lar in persons with a high level of physical activ-
ity and those with a low level (P = 0.19 for inter-
action in women and P = 0.37 for interaction in 
men). In a previous study, we found that BMI 
and physical activity were independently associ-
ated with the risk of death.1 In the Aerobics 
Center Longitudinal Study, a high BMI was the 
most important modifiable risk factor for low 
cardiorespiratory fitness, and obesity was found 
to offset the benefits of physical activity on fit-
ness.2 Furthermore, weight loss through lifestyle 
interventions was highly effective in improving 
physical fitness.3
In response to Logue et al.: although our 
Nurses’ Health Study and Health Professionals 
Follow-up Study cohorts were enrolled in 1976 
and 1986, respectively, our analyses included 
incident diabetes cases through January 1, 2010. 
Thus, our cohorts reflected contemporary popu-
lations of patients with diabetes. Because body 
weight is substantially influenced by disease se-
verity and methods of treatment, it is important 
to use BMI before or at the time of a diabetes 
diagnosis. As shown in our data and those of 
others, weight loss is common in patients with 
diabetes, even shortly before the diagnosis. There-
fore, use of the postdiagnosis weight increases 
the potential for reverse-causation biases.
Dixon and Kral note that overweight and 
obesity might be protective against premature 
death in older populations by providing meta-
bolic reserves, although this hypothesis has yet 
to be tested. However, among older participants 
(≥65 years of age) at diabetes diagnosis, we found 
no survival advantage associated with overweight 
or obesity. BMI is a less valid measure of excess 
body fat in elderly populations than in younger 
populations, owing to differential loss of muscle 
mass related to sarcopenia and increased frailty. 
Future studies involving elderly populations should 
pay particular attention to these methodologic 
issues, especially weight loss due to chronic dis-
eases, and should also include measures of body-
fat distribution such as waist circumference.
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Acute Osteomyelitis in Children
To the Editor: In their article on acute osteo-
myelitis in children, Peltola and Pääkkönen 
(Jan. 23 issue)1 proposed measurement of se-
rum C-reactive protein (CRP) levels and erythro-
cyte sedimentation rate, blood culture, and 
plain radiography for the primary evaluation of 
a child with presumed acute osteomyelitis. The 
first step in their algorithm that initiates action 
(further evaluation) is elevation of CRP levels or 
the erythrocyte sedimentation rate, whereas 
normal CRP levels and erythrocyte sedimenta-
tion rates indicate observation and later reeval-
uation or, if clinically indicated, the same evalu-
ation as for an elevation of either value. Given 
that an elevated erythrocyte sedimentation rate 
is not specific for osteomyelitis,2,3 and that a 
normal rate persists long after the development 
of osteomyelitis (long after CRP levels become 
elevated),4 there is, in our opinion, no evidence 
for measuring the erythrocyte sedimentation 
rate in patients with acute disease. The relative-
ly low cost of measuring the erythrocyte sedi-
mentation rate may argue in its favor, but every 
test is expensive if it does not improve diagnos-
tic specificity or sensitivity, particularly when 
ordered frequently. Furthermore, a false posi-
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